EpiPen Alternative Developer Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside

Cantor started covering up Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company with five commercialized products.

The company also works with pharmaceutical companies to commercialize new molecules using its technologies, such as PharmFilm. Aquestive is commercializing a late-stage proprietary product candidate for severe allergic reactions, including anaphylaxis, and an early-stage topical epinephrine prodrug gel for several dermatological conditions.

Cantor emphasizes that the company’s secret sauce focuses on its PharmFilm technology, which delivers active pharmaceutical ingredients via oral routes (e.g. buccal, sublingual and lingual). The heart of the story right now is Anaphylm, which is in the pre-NDA stage for Type 1 allergic reactions.

Cantor initiates with an Overweight rating and a price forecast of $17.

Also read: Optimism around Aquestive as it moves forward with severe allergy and baldness candidate

Earlier this month, the company reaffirmed guidance for filing a new drug application in the first quarter of 2025 for Anaphylm and confirmed that no additional clinical studies in adults are required before filing an NDA. The company has begun pediatric trials in the US and Canada.

Cantor writes that Aquestive’s stock is trading well below estimated peak sales for Anaphylm, despite the company producing significant data supporting its similar profile to epinephrine autoinjectors (and, in some situations, improvements).

“We would be buyers based on the potential of this program alone and we think the shares could rise >200% in 2025 if it is approved,” the Cantor analyst wrote.

Cantor writes that Anaphylm’s sublingual epinephrine could shake up the epinephrine auto-injector market if:

• The product is highly portable, about the size of a postage stamp, and fits in a pocket or behind a cell phone.

• It could be faster and easier to use than traditional auto-injectors, with fewer steps, which could make it more attractive to patients and healthcare providers.

Anaphylm U.S. marketing application filings make up the bulk of Cantor’s revenue forecasts for Aquestive.

Price promotion: AQST stock is up 7.31% to $3.86 at last check on Tuesday.

Read next:

Image: Shutterstock/Andrey_Popov.

View more analyst ratings for AQST

View the latest analyst ratings

UNLOCKED: 5 NEW ACTS EVERY WEEK. Click now to get the best trading ideas every dayplus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Story continues